Literature DB >> 16329135

Tumor suppressive maspin and epithelial homeostasis.

Jaron Lockett1, Shuping Yin, Xiaohua Li, Yonghong Meng, Shijie Sheng.   

Abstract

Maspin is a 42-kDa novel serine protease inhibitor (serpin) with multifaceted tumor suppressive activities. To date, the consensus that maspin expression predicts a better prognosis still largely holds for breast, prostate, colon, and oral squamous cancers. Interestingly, however, more detailed analyses revealed a biphasic expression pattern of maspin in early steps of tumorigenicity and re-expression of maspin in dormant cancer metastatic revertants. These data suggest a sensitivity of maspin expression to changes of epithelial microenvironments, and a role of maspin in epithelial homeostasis. Experimental evidence consistently showed that maspin suppresses tumor growth, invasion and metastasis, induces tumor redifferentiation, and enhances tumor cell sensitivity to apoptosis. Maspin protein isolated from biological sources is a monomer, which is present as a secreted, a cytoplasmic, a nuclear, as well as a cell surface-associated protein. Nuclear maspin is associated with better prognoses of cancer. It is further noted that extracellular maspin is sufficient to block tumor induced extracellular matrix degradation, tumor cell motility and invasion, whereas intracellular maspin is responsible for the increased cellular sensitivity to apoptosis. Despite these exciting developments, the mechanistic studies of maspin have proven challenging primarily due to the lack of a prototype molecular model. Although the maspin sequence has overall homologies with other members in the serpin superfamily, it does not behave like a typical serpin, that is, non-inhibitory toward active serine proteases in solution. This novel feature is in line with the X-ray crystallographic evidence. Several recent studies dedicated to finding the maspin partners support a paradigm shift. The current review is intended to summarize these recent findings and discuss a new perspective of maspin in epithelial homeostasis. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16329135     DOI: 10.1002/jcb.20721

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  33 in total

Review 1.  Role of TLR2-dependent inflammation in metastatic progression.

Authors:  Sunhwa Kim; Michael Karin
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.

Authors:  Fulvio Lonardo; Xiaohua Li; Alexander Kaplun; Ayman Soubani; Seema Sethi; Shirish Gadgeel; Shijie Sheng
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 3.  The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin.

Authors:  Margarida M Bernardo; Sijana H Dzinic; Maria J Matta; Ivory Dean; Lina Saker; Shijie Sheng
Journal:  J Cell Biochem       Date:  2017-03-21       Impact factor: 4.429

4.  HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Authors:  Xiaohua Li; Alexander Kaplun; Fulvio Lonardo; Elisabeth Heath; Fazlul H Sarkar; Jonathan Irish; Wael Sakr; Shijie Sheng
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

5.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

Review 6.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

7.  Expression of CD34 and maspin in ameloblastoma from a West African subpopulation.

Authors:  S E Udeabor; A O Adisa; B Kolude; M Barbeck; C J Kirkpatrick; R A Sader; S Ghanaati
Journal:  Tumour Biol       Date:  2014-05-09

Review 8.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

9.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

10.  Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.

Authors:  Ying Wai Lam; Yong Yuan; Jared Isaac; C V Suresh Babu; Jarek Meller; Shuk-Mei Ho
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.